Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cubist Gets Entereg And A Late-Stage Compound With Adolor Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal includes a contingent payment right tagged to Phase III-ready constipation drug ADL5945 that will provide extra consideration for Adolor shareholders if the drug reaches its upside potential.

You may also be interested in...



Naloxegol CV Safety Findings “Reassuring” – NEJM Study

AstraZeneca’s peripherally acting mu-opioid receptor antagonist was not associated with an increased incidence of major cardiovascular events in Phase III studies of chronic pain patients with opioid-induced constipation. An FDA advisory committee will review CV safety data for the drug class June 11-12.

Next Up For Cubist: A Future That Includes Optimer, Trius

Cubist Pharmaceuticals will strengthen its position in the challenging antibiotic market with the acquisitions of two rivals, Optimer Pharmaceuticals and Trius Therapeutics. But it was Cubist’s current strength that allowed it to get those deals done on favorable, risk-sharing terms.

Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius

Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel